Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA ® (erdafitinib) as a monotherapy for the treatment ...

A groundbreaking targeted treatment for the most common type of bladder cancer has been approved for use by the NHS, offering new hope to hundreds of patients. The National Institute of Health and ...

Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...

A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

(RTTNews) - ImmunityBio Inc. (IBRX) announced that the UK Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization for ANKTIVA (nogapendekin alfa inbakicept-pmln ...

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, ...

The first targeted treatment for the most common form of bladder cancer has been given the green light for NHS use. The recommendation on erdafitinib by the National Institute of Health and Care ...

The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...

The MarketWatch News Department was not involved in the creation of this content. -- ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate ...

insights from industryDr. Ignacio Duran & Alex FilicevasMedical Oncologist & Executive DirectorMarques de Valdecilla University Hospital & World Bladder Cancer Patient Coalition In this interview, Dr.

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...